Brokerages Set Edwards Lifesciences Co. (NYSE:EW) PT at $95.06

Shares of Edwards Lifesciences Co. (NYSE:EW) have been given an average recommendation of “Moderate Buy” by the twenty research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $95.06.

Several equities research analysts have weighed in on EW shares. Wells Fargo & Company increased their target price on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a report on Friday, April 26th. Citigroup upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $98.00 to $105.00 in a report on Wednesday, May 22nd. Deutsche Bank Aktiengesellschaft upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $86.00 to $103.00 in a report on Tuesday, May 14th. Evercore ISI cut their target price on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a report on Friday, April 26th. Finally, Stifel Nicolaus increased their target price on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a report on Friday, April 26th.

Edwards Lifesciences Trading Up 1.0 %

Shares of NYSE EW opened at $91.11 on Friday. The company’s 50 day simple moving average is $87.50 and its 200 day simple moving average is $84.95. Edwards Lifesciences has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The firm has a market capitalization of $54.90 billion, a P/E ratio of 39.27, a P/E/G ratio of 3.33 and a beta of 1.11. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. On average, analysts predict that Edwards Lifesciences will post 2.77 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $87.54, for a total transaction of $437,700.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $4,108,777.44. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $94.89, for a total value of $688,426.95. Following the completion of the sale, the chief financial officer now owns 19,074 shares in the company, valued at approximately $1,809,931.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $87.54, for a total transaction of $437,700.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $4,108,777.44. The disclosure for this sale can be found here. In the last 90 days, insiders sold 127,104 shares of company stock worth $11,267,464. 1.27% of the stock is owned by insiders.

Institutional Trading of Edwards Lifesciences

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Martin Capital Advisors LLP raised its position in shares of Edwards Lifesciences by 0.5% in the 4th quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock valued at $1,944,000 after buying an additional 128 shares in the last quarter. Legacy Wealth Asset Management LLC raised its position in shares of Edwards Lifesciences by 0.8% in the 4th quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock valued at $1,293,000 after buying an additional 134 shares in the last quarter. Chapin Davis Inc. raised its position in shares of Edwards Lifesciences by 1.7% in the 1st quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock valued at $817,000 after buying an additional 140 shares in the last quarter. Johnson Financial Group Inc. raised its position in shares of Edwards Lifesciences by 23.0% in the 4th quarter. Johnson Financial Group Inc. now owns 771 shares of the medical research company’s stock valued at $59,000 after buying an additional 144 shares in the last quarter. Finally, Valley National Advisers Inc. raised its position in shares of Edwards Lifesciences by 6.0% in the 1st quarter. Valley National Advisers Inc. now owns 2,677 shares of the medical research company’s stock valued at $255,000 after buying an additional 152 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.